Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Karis Bio is a clinical-stage biotechnology company that focuses on the development of regenerative cell therapy to treat cardiovascular disease. Our lead candidate, induced pluripotent stem cell-derived endothelial cell (iPSC-EC), is a cellular product that is currently in clinical development for the treatment of peripheral arterial disease (PAD) and coronary artery disease (CAD). We have also developed cell therapy with dir...
Karis Bio is a clinical-stage biotechnology company that focuses on the development of regenerative cell therapy to treat cardiovascular disease. Our lead candidate, induced pluripotent stem cell-derived endothelial cell (iPSC-EC), is a cellular product that is currently in clinical development for the treatment of peripheral arterial disease (PAD) and coronary artery disease (CAD). We have also developed cell therapy with directly reprogrammed endothelial cell (rEC) to treat various diseases that require new vessel formation. Our technologies have been developed in collaboration with Emory University.

List your booth number for exhibitions, ask us